Posts by David M. Langenau, PhD
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
Innovative Zebrafish Model Allows Visualization of Response to Cancer Drugs Over Time at Single-Cell Level and Leads to New Clinical Trial
Zebrafish generated by Massachusetts General Hospital Cancer Center and Massachusetts General Hospital's Department of Pathology researchers remain immunodeficient into adulthood and are transparent, allowing direct visualization of individual cells and their response to cancer therapy over time.
Biography
Dr. David Langenau received his BS and MS from the University of Notre Dame and his PhD in Biology and Biomedical Sciences from Harvard Medical School in 2004. He next completed his fellowship training at Children’s Hospital Boston in 2008. Along with Dr. A. Thomas Look, he is credited with developing the first transgenic zebrafish model of cancer. In his own group, he has made seminal discoveries underlying the pathogenesis of pediatric acute lymphoblastic leukemia and rhabdomyosarcoma.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
